Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model | Zendy

Isabel Jado | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model

Author(s) -

Isabel Jado

Publication year - 2003

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkg485

Subject(s) - lysin , lytic cycle , microbiology and biotechnology , peptidoglycan , amidase , lysozyme , biology , bacteriophage , streptococcus pneumoniae , in vivo , antibiotics , autolysin , phage therapy , enzyme , bacteria , muramidase , bacterial cell structure , virology , escherichia coli , biochemistry , virus , gene , genetics

Phage-coded lysins, i.e. murein hydrolases, are enzymes that destroy the cell wall of bacteria. A rapid killing of Streptococcus pneumoniae in the nasopharynx of mice has been described recently using a phage-coded murein hydrolase (enzybiotic). The in vivo effects of a dose-ranging treatment, using either of the phage-coded lytic enzymes Cpl-1 lysozyme or the Pal amidase, have been investigated here in a murine sepsis model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research